FIG. 3.

Flow cytometry analysis of CD18⁺ cells in peripheral blood of CLAD dogs following infusion of transduced CD34⁺ cells. (A) Levels of CD18⁺ peripheral blood leukocytes following treatment with the hPGK-cCD18 vector–treated dogs. (B) Levels of CD18⁺ leukocytes following treatment for the MSCV-cCD18 vector–treated dogs. (C) Dot plots of CD18⁺ peripheral blood leukocytes (PBL) subsets: neutrophils, CD3⁺ T lymphocytes, and CD14⁺ monocytes in the LV vector–treated CLAD dogs and a normal control are shown. Data points are shown at 52 weeks following infusion. CD18⁺ expression (x-axis) is plotted versus side scatter (y-axis). The percentage of CD18⁺ cells is indicated in the upper right-hand corner of each box. (D) Genomic DNA was extracted from peripheral blood leukocytes 52 weeks after gene therapy and the vector copy number was determined by real-time quantitative PCR.